A CB1 receptor enhancer reduced opioid withdrawal symptoms in mice without cannabis-like side effects

The CB1 receptor positive allosteric modulator ZCZ011 fully blocked opioid withdrawal-induced diarrhea and weight loss in mice without producing the side effects associated with THC.

Dodu, Julien C et al.·The Journal of pharmacology and experimental therapeutics·2022·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-03813Animal StudyPreliminary Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

ZCZ011 completely eliminated naloxone-precipitated diarrhea and weight loss in oxycodone-dependent mice and reduced paw flutters by about half. These effects were mediated specifically through CB1 receptors, confirmed by antagonist reversal and CB1 knockout mice. Unlike THC, ZCZ011 did not produce overt cannabimimetic behavioral effects.

Key Numbers

ZCZ011 fully blocked withdrawal-induced diarrhea and weight loss, reduced paw flutters by ~50%, had unreliable effects on head shakes, and did not affect jumping.

How They Did This

Mice were made opioid-dependent using escalating oxycodone doses, then given naloxone to precipitate withdrawal. ZCZ011 was tested against withdrawal signs including diarrhea, weight loss, jumping, paw flutters, and head shakes. CB1 and CB2 antagonists and CB1 knockout mice were used to confirm the mechanism.

Why This Research Matters

Current opioid withdrawal treatments have abuse liability or limited effectiveness. A CB1 enhancer that reduces withdrawal without cannabis-like intoxication could offer a new treatment approach.

The Bigger Picture

Positive allosteric modulators work by enhancing the body's own endocannabinoid signaling rather than directly activating receptors, which may explain the reduced side effect profile compared to THC.

What This Study Doesn't Tell Us

Mouse model only. Did not block all withdrawal signs (jumping was unaffected). Doses used may not translate to humans. Long-term safety of CB1 PAMs is unknown.

Questions This Raises

  • ?Would ZCZ011 or similar CB1 PAMs be effective in human opioid withdrawal?
  • ?Could combining a CB1 PAM with existing treatments improve outcomes across all withdrawal symptoms?

Trust & Context

Key Stat:
Fully blocked withdrawal diarrhea and weight loss via CB1 mechanism
Evidence Grade:
Well-designed preclinical study with mechanism confirmation, but limited to mice and did not address all withdrawal symptoms.
Study Age:
Published in 2022.
Original Title:
The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.
Published In:
The Journal of pharmacology and experimental therapeutics, 380(1), 1-14 (2022)
Database ID:
RTHC-03813

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

How is this different from using THC for opioid withdrawal?

Unlike THC, which directly activates CB1 receptors and causes intoxication, ZCZ011 enhances the receptor's response to the body's own endocannabinoids. This produced withdrawal relief without the psychoactive side effects, tolerance, or dependence seen with THC.

Did it eliminate all withdrawal symptoms?

No. It fully blocked diarrhea and weight loss, reduced paw flutters by half, but did not affect jumping behavior. Its effects on head shakes were inconsistent.

Read More on RethinkTHC

Cite This Study

RTHC-03813·https://rethinkthc.com/research/RTHC-03813

APA

Dodu, Julien C; Moncayo, Rebecca K; Damaj, M Imad; Schlosburg, Joel E; Akbarali, Hamid I; O'Brien, Lesley D; Kendall, Debra A; Wu, Zhixing; Lu, Dai; Lichtman, Aron H. (2022). The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.. The Journal of pharmacology and experimental therapeutics, 380(1), 1-14. https://doi.org/10.1124/jpet.121.000723

MLA

Dodu, Julien C, et al. "The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.." The Journal of pharmacology and experimental therapeutics, 2022. https://doi.org/10.1124/jpet.121.000723

RethinkTHC

RethinkTHC Research Database. "The Cannabinoid Receptor Type 1 Positive Allosteric Modulato..." RTHC-03813. Retrieved from https://rethinkthc.com/research/dodu-2022-the-cannabinoid-receptor-type

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.